Captrust Financial Advisors Sells 2,769 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors decreased its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 48.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,953 shares of the company’s stock after selling 2,769 shares during the period. Captrust Financial Advisors’ holdings in Axsome Therapeutics were worth $250,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Strategic Financial Concepts LLC bought a new position in shares of Axsome Therapeutics in the 4th quarter valued at $2,599,000. Intech Investment Management LLC boosted its holdings in shares of Axsome Therapeutics by 46.5% during the 4th quarter. Intech Investment Management LLC now owns 16,028 shares of the company’s stock valued at $1,356,000 after acquiring an additional 5,087 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Axsome Therapeutics during the 4th quarter valued at $14,771,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Axsome Therapeutics by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company’s stock valued at $27,755,000 after acquiring an additional 5,438 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new stake in shares of Axsome Therapeutics during the 4th quarter valued at $395,000. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

Shares of AXSM opened at $105.76 on Thursday. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $139.13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The business’s 50 day moving average price is $109.68 and its two-hundred day moving average price is $105.46. The firm has a market cap of $5.21 billion, a PE ratio of -17.66 and a beta of 0.46.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. On average, equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, Director Mark Coleman sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $107.49, for a total value of $322,470.00. Following the completion of the sale, the director now owns 54,137 shares of the company’s stock, valued at approximately $5,819,186.13. This trade represents a 5.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 22.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on AXSM shares. Needham & Company LLC reaffirmed a “buy” rating and set a $153.00 target price on shares of Axsome Therapeutics in a report on Tuesday, April 1st. Wells Fargo & Company reaffirmed an “overweight” rating and set a $165.00 target price (up from $160.00) on shares of Axsome Therapeutics in a report on Tuesday, May 6th. Morgan Stanley lifted their target price on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft started coverage on Axsome Therapeutics in a report on Tuesday, February 11th. They set a “buy” rating and a $176.00 target price on the stock. Finally, Leerink Partners lifted their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $172.14.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.